Blog - Page 708 of 5748 - QualityStocks

WednesdaySep 06, 2023 9:00 am

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) Poised to Grow in Country with Exceptional Economic Forecast

Guyana president reports country has experienced a threefold increase in its economy since 2020 Projections forecast continued average annual growth rate for the country of 25% between 2023 and 2026 Within this environment, Reunion Gold is moving its Oko West project forward on the path to development, which could further contribute to the country’s growth As Guyana reports continued economic growth and recovery, Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF) is strengthening its position as a leading gold explorer in the Guiana Shield. “Guyana has undergone a remarkable economic transformation, experiencing a threefold increase in its economy since 2020,” reported the…

TuesdaySep 05, 2023 12:00 pm

QualityStocksNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference

Longeveron (NASDAQ: LGVN, LGVNR), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty, today announced that its management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference. The event is slated to take place in New York City from Sept. 11-13, 2023. Longeveron’s CEO Wa’el Hashad will give a pre-recorded presentation highlighting the company’s cellular therapy programs, which will be available on-demand by clicking here for the duration of the conference. The company’s CFO Lisa Locklear will also attend the…

TuesdaySep 05, 2023 11:46 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, in New York City. According to the announcement, CNS Pharmaceuticals CEO Climaco is scheduled to present during the two-day conference; his live webcast presentation is scheduled for Wednesday, Sept. 13, at 10:30 a.m. ET. In addition to the presentation, key CNPS officials will be available to participate in in-person and virtual one-on-one meetings with…

TuesdaySep 05, 2023 11:15 am

NECANN’s New York Cannabis & Hemp Convention Set to Empower the Cannabis Industry

Investors, business executives, researchers, and industry leaders, are invited to attend NECANN’s New York Cannabis & Hemp Convention to be held in Albany, New York from September 29 – 30, 2023. The highly anticipated event will focus on the latest trends in the cannabis and hemp industry. The convention serves as a unique platform to connect with industry leaders and explores the limitless possibilities within the cannabis and hemp sectors. Featuring thought-provoking exhibits and engaging sessions, the New York Cannabis & Hemp Convention is designed to create a lasting impact on the participants. The immersive atmosphere will encourage attendees to…

TuesdaySep 05, 2023 11:03 am

QualityStocksNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) CEO to Present at Upcoming H.C. Wainwright Conference

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, has announced that it will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference taking place on Monday, Sept. 11, 2023. The announcement reads, “Knightscope’s Chairman and CEO, William Santana Li, will deliver a corporate overview followed by question-and-answer sessions with analysts and attendees. The event begins at 7:00 a.m. ET and will be available on demand by registering here.” To view the full press release, visit https://ibn.fm/5Kx4V About Knightscope, Inc. Knightscope is an advanced public safety technology company that builds fully…

TuesdaySep 05, 2023 10:30 am

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) CEO Discusses Metal-Rich Properties, Potential in Recent Podcast

Tellurium is listed by the United States and Canadian governments as a critical metal “We have an interesting critical metal that is going to be much of demand in the future as well as high-grade precious metals,” states FSTTF CEO The company’s two properties — Deer Horn Project in British Columbia and Klondike tellurium-gold property in Colorado — anchor a diversified search for metals Tellurium is gaining recognition in a world increasingly focused on renewable sources of energy. Listed on both the U.S. (https://ibn.fm/bF1X8) and Canada (https://ibn.fm/jfQXH) list of critical metals, tellurium is a key component of solar panels. First Tellurium’s…

TuesdaySep 05, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline

U.S.-based gene therapy developer Genprex, Inc. is developing new therapies for fighting cancer tumors and diabetes The company’s gene therapies for battling types 1 and 2 diabetes use a simple endoscopic procedure to introduce select insulin-boosting genes directly to the pancreas to combat insulin decline factors in the body The company is working with research collaborators at the University of Pittsburgh (Pitt) and recently announced a new license agreement in relation to a gene therapy for both Type 1 and Type 2 diabetes The company’s novel infusion process using related gene therapy has shown statistically significant results in preclinical testing…

TuesdaySep 05, 2023 9:00 am

As REE Miners Face Impediments to Refining Independence, Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Develops Supply Chain Technology Based in North America

Ucore Rare Metals Inc. is demonstrating the rare earth feedstock refining capabilities of its proprietary RapidSX(TM) processing technology at an Ontario facility while preparing to build a commercial plant in Louisiana, developing a North America-based supply chain for critical tech metals Rare earth element (“REE”) processing is currently almost exclusively controlled worldwide by the People’s Republic of China, and governments as well as industry players are searching for solutions to develop rare earth sourcing not reliant on Chinese industry and its government’s policies Companies that have been involved in mining REEs have thus far encountered significant impediments to their efforts…

FridaySep 01, 2023 3:45 pm

QualityStocksNewsBreaks – Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) (FWB: HF2) Looking to Improve North America’s Graphite Infrastructure Efficiencies to Meet Surging Demand

Reflex (CSE: RFLX) (OTCQB: RFLXF) (FWB: HF2) is advancing its flagship Ruby Graphite Project in Beaverhead County in southwestern Montana. “With its ‘mine-to-market’ strategy, Reflex aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications… Preliminary results from the TDEM and magnetic survey have demonstrated promising anomalies, indicating the presence of conductive structures, several new anomalies, and potential graphite mineral deposits within the Ruby Graphite property. The survey data will be integrated with existing…

FridaySep 01, 2023 2:43 pm

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently received coverage in analysis by Aegis Capital Corp. The report, which reiterated a buy recommendation and $70 target price for BVXV, contained analysis highlighting a deal valued at approximately $2.4 billion for Eli Lilly and Company’s (NYSE: LLY) acquisition of DICE Therapeutics Inc. (NASDAQ: DICE), a biopharmaceutical company that develops oral therapeutic candidates – such as DC-806 and DC-853, both oral interleukin-17 (“IL-17”) inhibitors – currently in…

Site Search

Company Search